149 related articles for article (PubMed ID: 6173346)
21. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
Takano S; Gately S; Neville ME; Herblin WF; Gross JL; Engelhard H; Perricone M; Eidsvoog K; Brem S
Cancer Res; 1994 May; 54(10):2654-60. PubMed ID: 7513254
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis.
Blei F; Wilson EL; Mignatti P; Rifkin DB
J Cell Physiol; 1993 Jun; 155(3):568-78. PubMed ID: 7684043
[TBL] [Abstract][Full Text] [Related]
23. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
24. [Animal experiment studies on the role of inflammation mediators in corneal neovascularization].
Rochels R
Doc Ophthalmol; 1984 May; 57(3):215-62. PubMed ID: 6205837
[TBL] [Abstract][Full Text] [Related]
25. [Significance of an angiogenic factor (in omental lipid) for the vascularization of the cornea].
Rossa V; Weber U; Menzel H
Klin Monbl Augenheilkd; 1987 Jun; 190(6):501-4. PubMed ID: 2442446
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen Activators and Inhibitors in the Corneas of Mice Infected with Pseudomonas aeruginosa.
Berk RS; Katar M; Dong Z; Day DE
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1561-7. PubMed ID: 11381061
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
28. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activation transforms the morphology of quiescent 3T3 cell monolayers and initiates growth.
Whur P; Silcox JJ; Boston JA; Williams DC
Br J Cancer; 1979 Jun; 39(6):718-30. PubMed ID: 156038
[TBL] [Abstract][Full Text] [Related]
30. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
31. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
32. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.
Holmberg L; Kristoffersson AC; Lecander I; Wallén P; Astedt B
Scand J Clin Lab Invest; 1982 Jun; 42(4):347-54. PubMed ID: 6753100
[TBL] [Abstract][Full Text] [Related]
33. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
[TBL] [Abstract][Full Text] [Related]
34. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
[TBL] [Abstract][Full Text] [Related]
35. Loss of cell viability dramatically elevates cell surface plasminogen binding and activation.
O'Mullane MJ; Baker MS
Exp Cell Res; 1998 Jul; 242(1):153-64. PubMed ID: 9665813
[TBL] [Abstract][Full Text] [Related]
36. [Pathobiochemical aspects of corneal neovascularization].
Rochels R
Fortschr Med; 1984 Feb; 102(5):101-2. PubMed ID: 6199272
[TBL] [Abstract][Full Text] [Related]
37. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
38. The appearance and possible role of plasminogen activator of urokinase type (u-PA) activity in the cornea related to soft contact lens wear in rabbits.
Cejková J
Doc Ophthalmol; 1998; 95(2):165-79. PubMed ID: 10431800
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of the plasminogen activator from HeLa cells by peptides of arginine chloromethyl ketone.
Coleman P; Kettner C; Shaw E
Biochim Biophys Acta; 1979 Jul; 569(1):41-51. PubMed ID: 111716
[TBL] [Abstract][Full Text] [Related]
40. Plasminogen activators (urokinase) mediate neovascularization: possible role in tumor angiogenesis.
Goldfarb RH; Ziche M; Murano G; Liotta LA
Semin Thromb Hemost; 1986 Oct; 12(4):337-8. PubMed ID: 2431485
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
